Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

3mg Liraglutide for Overweight or Obesity

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03885297
Recruitment Status : Unknown
Verified March 2019 by University Hospitals Coventry and Warwickshire NHS Trust.
Recruitment status was:  Recruiting
First Posted : March 21, 2019
Last Update Posted : March 21, 2019
Sponsor:
Collaborators:
Kingston University
University of Warwick
University of Birmingham
Information provided by (Responsible Party):
University Hospitals Coventry and Warwickshire NHS Trust

Tracking Information
First Submitted Date February 27, 2019
First Posted Date March 21, 2019
Last Update Posted Date March 21, 2019
Actual Study Start Date January 18, 2019
Estimated Primary Completion Date July 18, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: March 19, 2019)
Weight changes related to treatment [ Time Frame: 6 months ]
Weight reduction in kilograms from baseline while on treatment with 3mg Liraglutide once daily in patients with overweight (BMI: ≥27Kg/m2) or obesity (BMI: ≥30Kg/m2) with regards to:
Original Primary Outcome Measures Same as current
Change History No Changes Posted
Current Secondary Outcome Measures
 (submitted: March 19, 2019)
  • Changes in fat and lean mass while on treatment [ Time Frame: 6 months ]
    Fat and lean mass changes in percentages from baseline using air displacement plethysmography and bioelectrical impedance techniques while on treatment with 3mg Liraglutide once daily for overweight and obesity
  • Changes in an untargeted study of water-soluble metabolites (HILIC LCMS) while on treatment [ Time Frame: 6 months ]
    Ultra Performance Liquid Chromatography-Mass Spectrometry (UPLC-MS) will be performed to measure plasma changes of water-soluble metabolites (HILIC LCMS).
  • Changes in an untargeted study of lipid metabolites (C18 reversed phase LCMS) while on treatment [ Time Frame: 6 months ]
    Ultra Performance Liquid Chromatography-Mass Spectrometry (UPLC-MS) will be performed to measure plasma changes of lipid metabolites (C18 reversed phase LCMS)
  • Changes in the expression of miRNA-155 while on treatment. [ Time Frame: 6 months ]
    Decreased expression of miRNA-155 has been found during the adipogenic programming of both immortalized and primary hMSCs, suggesting that it acts as negative regulators of fat cell differentiation. We will measure this in plasma.
  • Changes in the expression of miRNA-221 while on treatment. [ Time Frame: 6 months ]
    Decreased expression of miRNA-221 has been found during the adipogenic programming of both immortalized and primary hMSCs, suggesting that it acts as negative regulators of fat cell differentiation. We will measure this in plasma.
  • Changes in the expression of miRNA-222 while on treatment. [ Time Frame: 6 months ]
    Decreased expression of miRNA-222, has been found during the adipogenic programming of both immortalized and primary hMSCs, suggesting that it acts as negative regulators of fat cell differentiation. We will measure this in plasma.
  • Changes in glucose and insulin from baseline. [ Time Frame: 6 months ]
    We will measure changes in serum glucose and insulin from baseline while on treatment using ELISA (enzyme-linked immunosorbent assay).
  • Changes in systolic blood pressure. [ Time Frame: 6 months ]
    We will measure systolic blood pressure changes from baseline while on treatment.
  • Changes diastolic blood pressure. [ Time Frame: 6 months ]
    We will measure diastolic blood pressure changes from baseline while on treatment.
  • Changes in heart rate. [ Time Frame: 6 months ]
    We will measure heart rate changes from baseline.
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title 3mg Liraglutide for Overweight or Obesity
Official Title Investigation of the Metabolic Effects of 3mg Liraglutide on Patients With Overweight or Obesity
Brief Summary

In this study investigators will investigate the beneficial metabolic sequelae of Liraglutide in patients with obesity or overweight; including changes in vital signs, anthropometric characteristics (weight, body mass index and body composition), biochemical parameters, metabolomics and micro-ribonucleotide acid (miRNA) molecules from blood tests. Liraglutide is a commercially available analogue of a gut hormone physiologically produced in our bowel in response to food, licenced for the treatment of overweight or obesity. Liraglutide will be offered to patients attending National Health System (NHS) or private clinics within indication and according to their agreed clinical management. Investigators aim to collect real-life information for this study along with planned clinical management from patients who agree to their treatment and to take part in our study. Patients will be able to withdraw from treatment and study at any time without giving any explanation.

If successful, this study will help us combine clinical, biochemical and molecular information which will allow us to gain deeper understanding on the mechanisms behind the beneficial metabolic effects of Liraglutide in overweight and obesity. Data generated from this study will hopefully help us acquire funding for a larger multicentre study; the results of which can have substantial impact on millions of people with overweight or obesity around the world.

Detailed Description

1) Obesity is a global pandemic with debilitating consequences. It affects both adults and children; however, the prevalence of overweight and obesity among children and adolescents aged 5-19 has risen dramatically from just 4% in 1975 to just over 18% in 2016, highlighting the seriousness of this problem. The rise has occurred similarly among both boys and girls: in 2016 18% of girls and 19% of boys were overweight. While just under 1% of children and adolescents aged 5-19 were obese in 1975, more 124 million children and adolescents (6% of girls and 8% of boys) were obese in 2016.

Obesity is a major risk factor for noncommunicable diseases such as:

  1. Cardiovascular diseases (mainly heart disease and stroke), which were the leading cause of death in United States of America(USA);
  2. Diabetes Mellitus
  3. Musculoskeletal disorders (especially osteoarthritis - a highly disabling degenerative disease of the joints);
  4. Some forms of malignancy (including endometrial, breast, ovarian, prostate, liver, gallbladder, kidney, and colon);
  5. Infertility in both women and men. The risk for these noncommunicable diseases increases, with increases in Body Mass Index (BMI).

2) Liraglutide is a derivative of human incretin (metabolic hormone) glucagon-like peptide-1 (GLP-1) that is used as a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Liraglutide is licenced in USA and in European Union (EU), including United Kingdom (UK) for the management of Type 2 Diabetes Mellitus (T2DM) and Obesity or overweight when one or more metabolic co-morbidities are present.

Saxenda (3mg Liraglutide once daily) is an Food & Drug Administration (FDA)-approved, prescription injectable Glucagon Like Peptide-1 (GLP-1) receptor agonist that, when used with a low-calorie diet and increased physical activity, can reduce excess weight in patients who are overweight (BMI ≥27Kg/m2) and additionally have weight-related medical problems (such as high blood pressure, high cholesterol, or insulin resistance/pre-diabetes), or obesity (BMI: >30Kg/m2) to lose weight. Saxenda is licensed and available in the UK for the management of obesity and overweight.

3) Metabolomics is the scientific study of chemical processes involving metabolites, the small molecule intermediates and products of metabolism. Specifically, metabolomics is the "systematic study of the unique chemical fingerprints that specific cellular processes leave behind", the study of their small-molecule metabolite profiles. The metabolome represents the complete set of metabolites in a biological cell, tissue, organ or organism, which are the end products of cellular processes. This in emerging area of metabolic research and in this study, will provide insight into the mechanisms through which 3mg Liraglutide improves weight and other metabolic sequelae (i.e glucose and lipids homeostasis) in humans during treatment. To the extend of our knowledge, there is a very limited number of such studies; none of which reporting on the effects of 3mg Liraglutide. Our collaborator Professor Gyanendra Tripathi has kindly agreed to fund costs for metabolomics analysis of our human samples. Metabolomics analysis of human serum or plasma samples is going to be performed by applying Ultra Performance Liquid Chromatography-Mass Spectrometry (UPLC-MS). UPLC-MS assay will provide untargeted study of water-soluble metabolites (HILIC LCMS) and untargeted study of lipid metabolites (C18 reversed phase LCMS). Analysis is going to be performed at School of Biosciences, University of Birmingham.

4) MicroRNA (abbreviated miRNA) is a small non-coding RNA molecule (containing about 22 nucleotides) found in plants, animals and some viruses, that functions in RNA silencing and post-transcriptional regulation of gene expression. While most miRNAs are located within the cell, some miRNAs, commonly known as circulating miRNAs or extracellular miRNAs, have also been found in extracellular environment, including various biological fluids and cell culture media. MiRNAs play crucial roles in the regulation of stem cell progenitors differentiating into adipocytes. Studies to determine what role pluripotent stem cells play in adipogenesis, were examined in the immortalized human bone marrow-derived stromal cell line hMSC-Tert20. Decreased expression of miRNA-155, miRNA-221, and miRNA-222, have been found during the adipogenic programming of both immortalized and primary human Mesenchymal Stem Cells (hMSCs), suggesting that they act as negative regulators of differentiation. Conversely, ectopic expression of the miRNAs 155,221, and 222 significantly inhibited adipogenesis and repressed induction of the master regulators Peroxisome proliferator-activated receptor gamma(PPARγ) and CCAAT/enhancer-binding protein alpha (CEBPA). This paves the way for possible genetic obesity treatments. Our goal is however to see if treatment with 3mg Liraglutide will influence circulating miRNA levels. To the extent of our knowledge there is currently no study reporting this.

Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population Investigators don't anticipate any specific difficulties with recruitment for this study as overweight and obesity are very common conditions, and there are very few licensed medical options offering substantial weight loss. Liraglutide is one of them. Additionally, investigators don't see any specific difficulties in managing this study as it will be " part and parcel" of our patients' routine clinical visits. Liraglutide is going to be offered to our patients as per clinical need and the decision to treat them with liraglutide is going to be made before their potential participation in our study. Patients therefore are not going to be receiving treatment because of their participation in our study.
Condition
  • Overweight
  • Obesity
  • Infertility, Female
Intervention
  • Drug: Saxenda
    Obesity pharmacotherapy
  • Other: Lifestyle modification
    Tier 3 NHS weight management
  • Diagnostic Test: Metabolomics
    Small molecule intermediates and products of metabolism
  • Diagnostic Test: miRNA
    Small non-coding RNA molecules
Study Groups/Cohorts Overweight/obese participants
Patients will be recruited prospectively from the weight management and Polycystic Ovary Syndrome (PCOS) clinics at University Hospitals Coventry and Warwickshire (UHCW) NHS Trust following discussion with their treating physician, who will also be a member of the research team and joint agreement on initiation of treatment with 3mg Liraglutide once daily as per clinical management plan. Patients will additionally receive standard NHS Tier 3 lifestyle advice and support for the duration of the study. Lifestyle modification aimed at weight loss will be delivered by a dietician or other trained health care professional within individual sessions for a period of 6 months. Finally, all patients will be able to withdraw from treatment and/or the study at any point without giving any explanation. This will have no impact in their clinical management.
Interventions:
  • Drug: Saxenda
  • Other: Lifestyle modification
  • Diagnostic Test: Metabolomics
  • Diagnostic Test: miRNA
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Unknown status
Estimated Enrollment
 (submitted: March 19, 2019)
100
Original Estimated Enrollment Same as current
Estimated Study Completion Date January 18, 2021
Estimated Primary Completion Date July 18, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Adult participants [age ≥18 y.o without upper age limit (to the discretion of the investigators)].
  • Body mass index (BMI) ≥ 30 kg/m2 without coexisting comorbidities or BMI ≥27Kg/m2 with comorbidities like hypertension, hyperlipidaemia, prediabetes or obstructive sleep apnoea.
  • Willing to comply with study requirements and able to give informed consent.

Exclusion Criteria:

  • Type 1 or Type 2 diabetes mellitus
  • History of chronic or acute pancreatitis
  • Known active hepatitis or active liver disease
  • Symptomatic gallstones or kidney stones, acute cholecystitis or history of duodenal inflammatory diseases including Crohn's Disease and Celiac Disease
  • Persistent anaemia, defined as haemoglobin<10 g/dl
  • Chronic or acute renal impairment (eGFR <30 ml/min/1.73m2)
  • Active systemic infection (sepsis)
  • Active malignancy within the last 5 years, including any form of thyroid cancer (including sporadic or familial medullary thyroid cancer) or personal, or family history of Multiple Endocrine Neoplasia type 2.
  • Active illicit substance abuse or alcoholism
  • Current pregnancy or breastfeeding at screening or 6 months previously
  • Donated blood during the preceding 3 months or intention to do so before the end of the study.
  • Any other mental or physical condition which, in the opinion of the Investigator, makes the subject a poor candidate for clinical trial participation.
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers Yes
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number NCT03885297
Other Study ID Numbers GD410218
250896 ( Registry Identifier: IRAS ID number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement
Plan to Share IPD: No
Responsible Party University Hospitals Coventry and Warwickshire NHS Trust
Study Sponsor University Hospitals Coventry and Warwickshire NHS Trust
Collaborators
  • Kingston University
  • University of Warwick
  • University of Birmingham
Investigators
Principal Investigator: Georgios K. Dimitriadis University Hospitals Coventry and Warwickshire NHS Trust
PRS Account University Hospitals Coventry and Warwickshire NHS Trust
Verification Date March 2019